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**Abstract**

Depression is one of the most prevalent and debilitating disorders worldwide that causes high social and economic burden. Available antidepressants require weeks or months to produce a therapeutic response, further highlighting the pressing need to develop rapidly acting antidepressant medications with limited side effects. The glutamate mechanisms in major depressive disorder have attracted much attention in recent years as a promising target for developing novel antidepressants. Our previous study showed that glycine site NMDA receptor antagonist 7-CTKA produces rapid antidepressant-like effects mediated by GSK3β and mTOR signaling. We also found high glutamate abundance accompanied by high expression of DAPK1 and phosphorylation of NR2B in the medial prefrontal cortex (mPFC) of rats that were subjected to chronic unpredictable mild stress (CUS), which could be mimicked by blockade of astrocytic glutamate transporter-1. Administration of DAPK1 inhibitor and selective NR2B antagonist but not NR2A antagonist produced a rapid antidepressant effect. Uncoupling DAPK1 from NR2B subunit by application of cell membrane permeable Tat-NR2B~CT~ peptide also produced a rapid antidepressant effect by reducing the immobility in the forced swim test (FST) and reversing CUS-induced decrease in sucrose preference. Moreover, selective NR2B antagonist did not produce rewarding effect. These findings suggest that DAPK1 interaction with NMDA receptor NR2B subunit acts as a critical component in the rapid antidepressant actions.

Inflammation can impact the glutamatergic system enhancing excitotoxicity and decreasing neuroplasticity. Using altered peptide ligand (APL) of myelin basic protein (MBP) to immunize rats, we found that myelin-derived altered peptides produced a prolonged antidepressant-like effect by reducing the immobility in the FST and preventing CUS-induced anhedonia. The behavioral outcome was accompanied by increased c-fos expression and restoration of p11 and BDNF levels in the mPFC and dentate gyrus (DG). Moreover, intra-mPFC infusion of lentiviral vectors containing short-hairpin RNA targeting p11 blunted the antidepressant-like effects. Our findings introduce a novel immune-based therapy for treatment of depression.

NMDA receptor trafficking and function are regulated by the receptor tyrosine kinase EphB2 through dynamic interacting NMDA receptors and Src-mediated tyrosine phosphorylation. We observed decrease in EphB2 level in the mPFC of mice that were susceptible to chronic social defeat stress. Activation of EphB2 receptors in the mPFC produced stress-resistant and antidepressant-like behavioral effects in susceptible mice, while EphB2 receptor knockdown increased the susceptibility to stress and induced depressive-like behaviors in a subthreshold chronic social defeat stress paradigm. These behavioral effects were associated with changes in the phosphorylation of cofilin and expression of some synaptic proteins and stress-induced spine remodeling in the mPFC. These results indicate that EphB2 is a critical regulator of stress vulnerability and might be a potential target for the treatment of depression.
